Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bliss long-term extension study of venlafaxine in Japanese pediatric patients with MDD or PDD
jRCT2031220357Recruiting
- Sponsor
- Viatris
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venlafaxine in major depressive disorder (MDD) and persistent depressive disorder (PDD), sponsored by Viatris. Primary endpoint: Safety outcomes (descriptive statistics). Started Jun 2023; status: recruiting.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on jRCT2031220357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220357.